Sejemnet Technology Software Development How a single pill could save millions of lives

How a single pill could save millions of lives

The new pill that could save billions of lives, according to a study, has been designed to kill the disease of aging and is likely to be available in two to three years.

The new treatment has been described as the ‘perfect pill’ by a US physician.

The results are from a new study which suggests the pill could be used to help save the lives of up to a million people.

A pill is a tiny, tiny capsule containing the active ingredients of a medicine that is injected into the body.

The drug, called rolucan, is a pill that contains the drug which is called ro-LUC-3.

The pill has been tested in animals and is designed to be injected into a person’s arm or foot.

In the study, researchers from the US National Institute on Aging looked at the effects of rolukan on mice, pigs and humans.

The findings showed that rolukaan was able to significantly reduce the time a person has to die of cardiovascular disease.

“We’ve had very good results from animal studies that we’ve been studying for years and now we’ve got good evidence that it works,” Dr Jennifer B. Shafer, a professor of medicine and a researcher at the National Institutes of Health, said.

The study was published in the journal PLOS ONE.

The researchers say roluzan could be a useful treatment for older adults with heart disease, cancer and other chronic diseases, as well as people who are suffering from arthritis, depression and diabetes.

The benefits of ro-luc-3 were greatest in those people who had a genetic predisposition for the disease, such as those who had an inherited gene mutation that increases their risk of developing the disease.

Dr Shafer said the new pill would likely be available by 2020 or 2021.

It could also be used in the future to treat other types of ageing, such, for instance, to treat the disease known as progressive multifocal leukoencephalopathy (PML), or PML-positive patients.

“There is a real potential for rolu-3 to help with aging and to potentially save the life of a patient,” Dr Shafers research fellow said.

“The benefit to us is that ro-lanu-1 and ro-lamu-4 can also be beneficial, as those are the two genes that are associated with PML.”

The pill is also being tested to treat certain cancers and cardiovascular conditions.

Dr B.

Shafer said roluban was “a big deal because it could potentially be a huge boon for older people, who are in the twilight of life and who may be at high risk of dying”.

She said that rolu-1 was involved in several pathways of ageing that are linked to other diseases, such cancer and cardiovascular diseases.

“But it is also a gene, and that gene is also involved in many different cancers,” she said.

In order to make the pill safe, rolue-3 has been made into a different type of pill, known as roluquelon, which can be injected directly into the arm or into a vein.

“It has been very effective at slowing down the progression of many of these diseases,” Dr B Shafer added.

The pills are now being tested in humans to see if they are effective at treating patients suffering from chronic conditions such as arthritis, Parkinson’s disease and multiple sclerosis.

It is hoped that roli-3 could eventually be used for the treatment of the ageing process in older adults.

A spokesperson for the National Institute of Aging said roliocan had been developed with the help of research from the National Heart, Lung, and Blood Institute.

The research was funded by the National Science Foundation.

The National Institutes on Aging have also funded the research.

The news comes as roluclas company, BioTec, which has developed the pill, said its results were preliminary and could change.

BioTech has also released a video which highlights its new pill, which uses rolunan to treat chronic obstructive pulmonary disease (COPD).

BioTect said roluunan was not used in humans and was not approved for humans for use in that country.

Bio Tect has also published results from a study in mice.

“In mice, we’ve found that rou-LUK-3 was able, in a small dose, to reverse the progression in a mouse model of COPD.

This is an exciting result,” Dr Srinivasan said.

Dr Sri Lakshmanan, a researcher in the research team, said that the study was designed to show that rolsutan was safe for humans and could be administered to people.

“This is a very exciting development because we have been studying roluenas use in the past and it has shown promise for human use,” Dr Lakshmanans study leader said.